at MarketWatch.com (May 15, 2013)
Vermillion (VRML) +29.4% premarket after the developer of diagnostic tests signs a cooperative...
Vermillion (VRML) +29.4% premarket after the developer of diagnostic tests signs a cooperative research and development agreement with the U.S. Army. A two-phase study will investigate the cost-benefit profile of OVA1 testing as a presurgical standard of care in women with pelvic masses, and assess OVA1 clinical utility in a managed care setting.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at MarketWatch.com (Mar 6, 2012)
at MarketWatch.com (Sep 29, 2011)
at MarketWatch.com (Sep 14, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs